Novopulm Novolizer (Budesonide)

Novopulm Novolizer delivers budesonide to the airways, targeting inflammatory pathways in chronic respiratory disease.

• Asthma: Improves symptom control and reduces the frequency of exacerbations.
• Chronic obstructive pulmonary disease (COPD): Lowers airway inflammation and helps maintain lung function.
• Allergic rhinitis: Provides local anti‑inflammatory effect that can relieve nasal symptoms when used as directed.

• Budesonide binds to glucocorticoid receptors in airway epithelial cells, modulating gene transcription to suppress pro‑inflammatory cytokines, inhibit mast cell activation, and reduce mucus production. This anti‑inflammatory action decreases airway hyper‑responsiveness and improves airflow in the respiratory tract.

Adverse reactions to inhaled budesonide are generally mild to moderate and relate to local exposure in the respiratory tract.

Common Side Effects

• Hoarseness or voice changes
• Oral thrush (candidiasis)
• Cough or throat irritation
• Upper respiratory tract infection
• Headache
• Nasal irritation

Serious or Rare Side Effects

• Paradoxical bronchospasm
• Severe fungal infection of the mouth or throat
• Adrenal suppression with high‑dose or prolonged use
• Pneumonia in patients with COPD
• Hypersensitivity reactions including anaphylaxis
• Glaucoma or cataract progression with long‑term use

When using Novopulm Novolizer, follow clinical guidance and monitor for systemic effects.

• Dose adjustment: Tailor dose to the lowest effective amount that maintains control.
• Monitoring: Periodically assess lung function and symptom control.
• Infections: Watch for signs of oral candidiasis; advise rinsing mouth after inhalation.
• Systemic exposure: Use caution in patients on systemic steroids or CYP3A4 inhibitors.
• Pregnancy and lactation: Evaluate risk‑benefit ratio with the prescriber.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Budesonide may interact with drugs that affect its metabolism or increase systemic corticosteroid effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.
• Systemic glucocorticoids: additive immunosuppressive effect.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise budesonide levels.
• Antifungal azoles: require periodic assessment of adrenal function.
• Ritonavir: may increase systemic exposure, monitor for adrenal suppression.
• Live vaccines: reduced efficacy due to immunosuppression.
• Diuretics: may potentiate fluid retention when systemic exposure is high.